Context Therapeutics Inc. (CNTX) research
Context Therapeutics Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.31
- As of
Context Therapeutics Inc. (CNTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for CNTX. Method and limitations.
Share the CNTX intelligence card
See the full CNTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CNTX on one page. Preview it with sample data, then open it live with a free account.
Preview the CNTX dossierActive signals for CNTX
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 90% of CNTX (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +469% to CNTX (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in CNTX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 59.4%, EPS $-0.15 vs $-0.0941 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 64% of CNTX (2026Q1)
FREE, NO ACCOUNT
Every signal on CNTX, as it fires
You are seeing 5 of 8 signals recorded on CNTX since 2026-05-29.
The five above landed across 3 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CNTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 21077P108 · 2026Q2 | $577K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 21077P108 · 2026Q2 | $82K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 21077P108 · 2026Q2 | $14K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 21077P108 · 2026Q2 | $10K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CNTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CNTX against its peers
CNTX's return on equity of -59.7% ranks in the 73rd percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | CNTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 509589 | n/a | 9 |
| Operating margin | n/a | -1489.3% | n/a | 8 |
| Net margin | n/a | -1329.3% | n/a | 8 |
| Return on equity | -59.7% | -124.7% | 73 | 12 |
Peers (16): RNAZ, ABVC, KYNB, ATYR, QNCX, CVM, LONA, BRNS, PSTV, SGMO, HOTH, GRDX, GNTA, PVCT, ALGS, COCP. Left out: CLCS (period gap), IGC (no annual filing), MDNAF (no annual filing), EVAX (no annual filing), TTIPF (no annual filing), QNTM (no annual filing), VICP (period gap), PLRZ (no annual filing), SEOVF (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CNTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CNTX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CNTXand get the insider, 13F, options, and confluence read in one view.